PMV Pharmaceuticals Inc (PMVP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.29+4.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
PMV Pharma aims to submit an NDA for rezatapopt in ovarian cancer in Q1 2027. The company has improved operating income from negative $25.2 million to negative $19.0 million recently. It beat earnings twice in the last year. These show progress toward a key regulatory milestone and better cost control.
PMV Pharma is still loss-making with negative EPS expected through 2027. Litigation and a recent earnings miss show risks. The company has no revenue yet and must prove its drug works and gains approval.
The market is selling off the stock amid losses and uncertainty. There is no clear consensus revenue growth or fair value priced in. Our view sees some progress but also high risk.
Breaks if: NDA submission delayed beyond 2027-Q1
Complete and submit the New Drug Application for rezatapopt targeting platinum-resistant/refractory ovarian cancer patients with TP53 Y220C mutation in the first quarter of 2027.
Stated as a priority in 4 of last 4 quarters. Management consistently anticipates submitting the NDA for rezatapopt in platinum-resistant/refractory ovarian cancer patients with TP53 Y220C mutation in Q1 2027. The clinical trial enrollment for this indication was completed by 2026-Q2, supporting progress toward this milestone. The trajectory is delivering as planned toward the NDA submission.
“Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027”
“PMV Pharma anticipates submitting a New Drug Application (NDA) for rezatapopt in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation in the first quarter of 2027.”
“PMV Pharma anticipates submitting a New Drug Application (NDA) for rezatapopt in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation in the first quarter of 2027.”
“Rezatapopt New Drug Application submission for platinum resistant/refractory ovarian cancer planned in first quarter of 2027”
Breaks if: Net income worse than -$18 million beyond 2026-Q1
Control operating expenses and cash burn to maintain financial stability and extend cash runway through mid-2027.
Stated as a priority in 4 of last 4 quarters. Cash and marketable securities declined from $112.9M at 2025-Q4 to $79.4M at 2026-Q2, with net loss improving from $21.2M in 2025-Q3 to $18.1M in 2026-Q2. Management maintains expected cash runway through Q2 2027. The trajectory shows controlled cash burn and expense management consistent with stated priorities.
“Cash, cash equivalents, and marketable securities of $79.4 million providing expected cash runway through second quarter of 2027”
“Cash, cash equivalents, and marketable securities of $93.5 million providing expected cash runway to end of second quarter of 2027”
“Cash and cash equivalents $37.98 million, marketable securities $74.96 million”
“Operating expenses and net loss reported with focus on managing cash burn”
Breaks if: Operating income worse than -$19 million beyond 2026-Q1
Control operating expenses and cash burn to maintain financial stability and extend cash runway through mid-2027.
Stated as a priority in 4 of last 4 quarters. Cash and marketable securities declined from $112.9M at 2025-Q4 to $79.4M at 2026-Q2, with net loss improving from $21.2M in 2025-Q3 to $18.1M in 2026-Q2. Management maintains expected cash runway through Q2 2027. The trajectory shows controlled cash burn and expense management consistent with stated priorities.
“Cash, cash equivalents, and marketable securities of $79.4 million providing expected cash runway through second quarter of 2027”
“Cash, cash equivalents, and marketable securities of $93.5 million providing expected cash runway to end of second quarter of 2027”
“Cash and cash equivalents $37.98 million, marketable securities $74.96 million”
“Operating expenses and net loss reported with focus on managing cash burn”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, given its focus on clinical development in the healthcare sector. The current thesis state reflects a recent shift from robust performance to a more fragile outlook.
The market appears to have priced in a high level of risk, as PMVP is currently loss-making and has a neutral recent financial performance. Expectations may be tempered due to the company's recent drop in industry performance.
Management has made progress in clinical trials and is focused on managing cash burn, but the overall earnings quality remains low. The trajectory for fundamentals is mixed, with some milestones being achieved but still facing high risk.
The future performance hinges on several factors, including management's ability to submit the NDA for rezatapopt as planned and the overall health of the healthcare sector. Additionally, any cuts to guidance or worsening economic conditions could negatively impact sentiment.
In the next 1 to 3 years, PMVP's outlook will depend on its clinical milestones and sector performance amidst high risk. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance dropped from the top half to the bottom half of its industry. This change indicates a decline in the reasons to own the company. The market reaction has been muted, with only a modest price movement since this shift.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.